Literature DB >> 22125664

Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.

Haibo Yu1, Meng Wu, Steven D Townsend, Beiyan Zou, Shunyou Long, J Scott Daniels, Owen B McManus, Min Li, Craig W Lindsley, Corey R Hopkins.   

Abstract

Herein we report the discovery, synthesis and evaluation of a series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides as selective KCNQ2 (K(v)7.2) and KCNQ4 (K(v)7.4) channel openers. The best compound, 1 (ML213) has an EC(50) of 230 nM (KCNQ2) and 510 nM (KCNQ4) and is selective for KCNQ2 and KCNQ4 channels versus a large battery of related potassium channels, as well as affording modest brain levels. This represents the first report of unique selectivity profile for KCNQ2 and KCNQ4 over the other channels (KCNQ1/3/5) and as such should prove to be a valuable tool compound for understanding these channels in regulating neuronal activity.

Entities:  

Year:  2011        PMID: 22125664      PMCID: PMC3223964          DOI: 10.1021/cn200065b

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  17 in total

Review 1.  The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update.

Authors:  Valentin K Gribkoff
Journal:  Expert Opin Ther Targets       Date:  2008-05       Impact factor: 6.902

2.  Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.

Authors:  Jinlong Qi; Fan Zhang; Yi Mi; Yan Fu; Wen Xu; Diqun Zhang; Yibing Wu; Xiaona Du; Qingzhong Jia; Kewei Wang; Hailin Zhang
Journal:  Eur J Med Chem       Date:  2011-01-22       Impact factor: 6.514

3.  Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.

Authors:  Paul C Fritch; Grant McNaughton-Smith; George S Amato; James F Burns; C Wesley Eargle; Rosemarie Roeloffs; William Harrison; Leslie Jones; Alan D Wickenden
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

4.  N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

Authors:  George Amato; Rosemarie Roeloffs; Greg C Rigdon; Brett Antonio; Theresa Mersch; Grant McNaughton-Smith; Alan D Wickenden; Paul Fritch; Mark J Suto
Journal:  ACS Med Chem Lett       Date:  2011-03-31       Impact factor: 4.345

5.  Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions.

Authors:  Zhaobing Gao; Tangzhi Zhang; Meng Wu; Qiaojie Xiong; Haiyan Sun; Yinan Zhang; Liansuo Zu; Wei Wang; Min Li
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

6.  Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides.

Authors:  Yong-Jin Wu; Li-Qiang Sun; Huan He; Jie Chen; John E Starrett; Pierre Dextraze; Jean-Paul Daris; Christopher G Boissard; Rick L Pieschl; Valentin K Gribkoff; Joanne Natale; Ronald J Knox; David G Harden; Mark W Thompson; William Fitzpatrick; David Weaver; Dedong Wu; Qi Gao; Steven I Dworetzky
Journal:  Bioorg Med Chem Lett       Date:  2004-09-06       Impact factor: 2.823

7.  In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models.

Authors:  Rosemarie Roeloffs; Alan D Wickenden; Christopher Crean; Stephen Werness; Grant McNaughton-Smith; James Stables; James O McNamara; Neil Ghodadra; Greg C Rigdon
Journal:  J Pharmacol Exp Ther       Date:  2008-06-24       Impact factor: 4.030

8.  KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum.

Authors:  Nanda A Singh; Peter Westenskow; Carole Charlier; Chris Pappas; Jonathan Leslie; Jessica Dillon; V Elving Anderson; Michael C Sanguinetti; Mark F Leppert
Journal:  Brain       Date:  2003-10-08       Impact factor: 13.501

9.  Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.

Authors:  R J Porter; A Partiot; R Sachdeo; V Nohria; W M Alves
Journal:  Neurology       Date:  2007-04-10       Impact factor: 9.910

10.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

Authors:  A Rostock; C Tober; C Rundfeldt; R Bartsch; J Engel; E E Polymeropoulos; B Kutscher; W Löscher; D Hönack; H S White; H H Wolf
Journal:  Epilepsy Res       Date:  1996-04       Impact factor: 3.045

View more
  27 in total

1.  Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.

Authors:  Hai-bo Yu; Bei-yan Zou; Xiao-liang Wang; Min Li
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

Review 2.  High throughput screening technologies for ion channels.

Authors:  Hai-bo Yu; Min Li; Wei-ping Wang; Xiao-liang Wang
Journal:  Acta Pharmacol Sin       Date:  2015-12-14       Impact factor: 6.150

3.  KV7 Channel Pharmacological Activation by the Novel Activator ML213: Role for Heteromeric KV7.4/KV7.5 Channels in Guinea Pig Detrusor Smooth Muscle Function.

Authors:  Aaron Provence; Damiano Angoli; Georgi V Petkov
Journal:  J Pharmacol Exp Ther       Date:  2017-10-30       Impact factor: 4.030

Review 4.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

5.  Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370.

Authors:  T A Jepps; B H Bentzen; J B Stott; O V Povstyan; K Sivaloganathan; W Dalby-Brown; I A Greenwood
Journal:  Br J Pharmacol       Date:  2014-08-14       Impact factor: 8.739

Review 6.  Urinary bladder smooth muscle ion channels: expression, function, and regulation in health and disease.

Authors:  John Malysz; Georgi V Petkov
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-06

7.  Characterization and functional roles of KCNQ-encoded voltage-gated potassium (Kv7) channels in human corpus cavernosum smooth muscle.

Authors:  Jun Ho Lee; Mee Ree Chae; Su Jeong Kang; Hyun Hwan Sung; Deok Hyun Han; Insuk So; Jong Kwan Park; Sung Won Lee
Journal:  Pflugers Arch       Date:  2020-01-09       Impact factor: 3.657

8.  Sequence determinants of subtype-specific actions of KCNQ channel openers.

Authors:  Alice W Wang; Runying Yang; Harley T Kurata
Journal:  J Physiol       Date:  2016-09-23       Impact factor: 5.182

9.  Kv7.5 Potassium Channel Subunits Are the Primary Targets for PKA-Dependent Enhancement of Vascular Smooth Muscle Kv7 Currents.

Authors:  Bharath K Mani; Christina Robakowski; Lyubov I Brueggemann; Leanne L Cribbs; Abhishek Tripathi; Matthias Majetschak; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2015-12-23       Impact factor: 4.436

10.  Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673.

Authors:  Lyubov I Brueggemann; Jennifer M Haick; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2014-06-18       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.